A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence

Malcolm S. Reid, Paul Casadonte, Sherryl Baker, Michael Sanfilipo, Dania Braunstein, Robert Hitzemann, Ann Montgomery, Dorota Majewska, James Robinson, John Rotrosen

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Aims: To conduct a medication screening trial on the efficacy of olanzapine, valproate or coenzyme Q10/L-carnitine combination versus placebo for the treatment of cocaine dependence. Design: A four-arm, modified blinded, parallel group study in an out-patient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting: The study was performed at the New York Medications Development Research Unit (MDRU). Participants: All participants met Diagnostic and Statistical Manual version IV (DSM-FV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2-week screening period. Sixty-eight participants were enrolled with 39 completing the study. Intervention: After a 2-week screening period, 68 subjects were assigned randomly to receive either olanzapine (10 mg/day), valproate (1500 mg/day), coenzyme Q10 (200 mg/day) and L-carnitine (500 mg/day) combination or placebo for an 8-week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements: Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self-report of drug use, and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs, and extrapyramidal side-effects tests. Results: Study retention was similar across all treatment groups, and all groups showed improvement across most measures of treatment efficacy over the duration of the study. None of the study medications, however, were superior to placebo on any of the primary or secondary outcome measures. Cocaine use, as measured by urine BE levels and self-report, was not significantly lower than placebo in any of the drug treatment groups. All study medications were equally well tolerated, and few medication side effects were observed. Conclusion: This pilot study does not support the effectiveness of olanzapine, valproate or coenzyme Q10/L-carnitine combination for the treatment of cocaine dependence.

Original languageEnglish (US)
Pages (from-to)43-57
Number of pages15
JournalAddiction
Volume100
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 2005

Fingerprint

coenzyme Q10
olanzapine
Cocaine-Related Disorders
Carnitine
Valproic Acid
Placebos
Cocaine
Urine
Self Report
Therapeutics
Outcome Assessment (Health Care)
Safety
Vital Signs
Pharmaceutical Preparations
Counseling
Outpatients

Keywords

  • Cocaine dependence
  • Coenzyme Q10
  • L-carnitine
  • Olanzapine
  • Treatment
  • Valproate

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. / Reid, Malcolm S.; Casadonte, Paul; Baker, Sherryl; Sanfilipo, Michael; Braunstein, Dania; Hitzemann, Robert; Montgomery, Ann; Majewska, Dorota; Robinson, James; Rotrosen, John.

In: Addiction, Vol. 100, No. SUPPL. 1, 03.2005, p. 43-57.

Research output: Contribution to journalArticle

Reid, MS, Casadonte, P, Baker, S, Sanfilipo, M, Braunstein, D, Hitzemann, R, Montgomery, A, Majewska, D, Robinson, J & Rotrosen, J 2005, 'A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence', Addiction, vol. 100, no. SUPPL. 1, pp. 43-57. https://doi.org/10.1111/j.1360-0443.2005.00990.x
Reid, Malcolm S. ; Casadonte, Paul ; Baker, Sherryl ; Sanfilipo, Michael ; Braunstein, Dania ; Hitzemann, Robert ; Montgomery, Ann ; Majewska, Dorota ; Robinson, James ; Rotrosen, John. / A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. In: Addiction. 2005 ; Vol. 100, No. SUPPL. 1. pp. 43-57.
@article{a789ecb712e74e1d954c6763e55904cc,
title = "A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence",
abstract = "Aims: To conduct a medication screening trial on the efficacy of olanzapine, valproate or coenzyme Q10/L-carnitine combination versus placebo for the treatment of cocaine dependence. Design: A four-arm, modified blinded, parallel group study in an out-patient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting: The study was performed at the New York Medications Development Research Unit (MDRU). Participants: All participants met Diagnostic and Statistical Manual version IV (DSM-FV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2-week screening period. Sixty-eight participants were enrolled with 39 completing the study. Intervention: After a 2-week screening period, 68 subjects were assigned randomly to receive either olanzapine (10 mg/day), valproate (1500 mg/day), coenzyme Q10 (200 mg/day) and L-carnitine (500 mg/day) combination or placebo for an 8-week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements: Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self-report of drug use, and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs, and extrapyramidal side-effects tests. Results: Study retention was similar across all treatment groups, and all groups showed improvement across most measures of treatment efficacy over the duration of the study. None of the study medications, however, were superior to placebo on any of the primary or secondary outcome measures. Cocaine use, as measured by urine BE levels and self-report, was not significantly lower than placebo in any of the drug treatment groups. All study medications were equally well tolerated, and few medication side effects were observed. Conclusion: This pilot study does not support the effectiveness of olanzapine, valproate or coenzyme Q10/L-carnitine combination for the treatment of cocaine dependence.",
keywords = "Cocaine dependence, Coenzyme Q10, L-carnitine, Olanzapine, Treatment, Valproate",
author = "Reid, {Malcolm S.} and Paul Casadonte and Sherryl Baker and Michael Sanfilipo and Dania Braunstein and Robert Hitzemann and Ann Montgomery and Dorota Majewska and James Robinson and John Rotrosen",
year = "2005",
month = "3",
doi = "10.1111/j.1360-0443.2005.00990.x",
language = "English (US)",
volume = "100",
pages = "43--57",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence

AU - Reid, Malcolm S.

AU - Casadonte, Paul

AU - Baker, Sherryl

AU - Sanfilipo, Michael

AU - Braunstein, Dania

AU - Hitzemann, Robert

AU - Montgomery, Ann

AU - Majewska, Dorota

AU - Robinson, James

AU - Rotrosen, John

PY - 2005/3

Y1 - 2005/3

N2 - Aims: To conduct a medication screening trial on the efficacy of olanzapine, valproate or coenzyme Q10/L-carnitine combination versus placebo for the treatment of cocaine dependence. Design: A four-arm, modified blinded, parallel group study in an out-patient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting: The study was performed at the New York Medications Development Research Unit (MDRU). Participants: All participants met Diagnostic and Statistical Manual version IV (DSM-FV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2-week screening period. Sixty-eight participants were enrolled with 39 completing the study. Intervention: After a 2-week screening period, 68 subjects were assigned randomly to receive either olanzapine (10 mg/day), valproate (1500 mg/day), coenzyme Q10 (200 mg/day) and L-carnitine (500 mg/day) combination or placebo for an 8-week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements: Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self-report of drug use, and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs, and extrapyramidal side-effects tests. Results: Study retention was similar across all treatment groups, and all groups showed improvement across most measures of treatment efficacy over the duration of the study. None of the study medications, however, were superior to placebo on any of the primary or secondary outcome measures. Cocaine use, as measured by urine BE levels and self-report, was not significantly lower than placebo in any of the drug treatment groups. All study medications were equally well tolerated, and few medication side effects were observed. Conclusion: This pilot study does not support the effectiveness of olanzapine, valproate or coenzyme Q10/L-carnitine combination for the treatment of cocaine dependence.

AB - Aims: To conduct a medication screening trial on the efficacy of olanzapine, valproate or coenzyme Q10/L-carnitine combination versus placebo for the treatment of cocaine dependence. Design: A four-arm, modified blinded, parallel group study in an out-patient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting: The study was performed at the New York Medications Development Research Unit (MDRU). Participants: All participants met Diagnostic and Statistical Manual version IV (DSM-FV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2-week screening period. Sixty-eight participants were enrolled with 39 completing the study. Intervention: After a 2-week screening period, 68 subjects were assigned randomly to receive either olanzapine (10 mg/day), valproate (1500 mg/day), coenzyme Q10 (200 mg/day) and L-carnitine (500 mg/day) combination or placebo for an 8-week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements: Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self-report of drug use, and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs, and extrapyramidal side-effects tests. Results: Study retention was similar across all treatment groups, and all groups showed improvement across most measures of treatment efficacy over the duration of the study. None of the study medications, however, were superior to placebo on any of the primary or secondary outcome measures. Cocaine use, as measured by urine BE levels and self-report, was not significantly lower than placebo in any of the drug treatment groups. All study medications were equally well tolerated, and few medication side effects were observed. Conclusion: This pilot study does not support the effectiveness of olanzapine, valproate or coenzyme Q10/L-carnitine combination for the treatment of cocaine dependence.

KW - Cocaine dependence

KW - Coenzyme Q10

KW - L-carnitine

KW - Olanzapine

KW - Treatment

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=20144364480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144364480&partnerID=8YFLogxK

U2 - 10.1111/j.1360-0443.2005.00990.x

DO - 10.1111/j.1360-0443.2005.00990.x

M3 - Article

VL - 100

SP - 43

EP - 57

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - SUPPL. 1

ER -